Publications by authors named "Eve Versage"

Claim this Profile
S
Safety, Tolerability, and Immunogenicity of aH5N1 Vaccine in Adults with and Without Underlying Immunosuppressive Conditions.
Peter Malfertheiner, Eve Versage, Esther Van Twuijver, Giuliano Rizzardini, Matthew Hohenboken

Vaccines (Basel)· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Tolerability, and Immunogenicity of aH5N1 Vaccine in Adults with and without Underlying Medical Conditions.
Tomas Jelinek, Tino F Schwarz, Emil Reisinger, Peter Malfertheiner, Eve Versage

Vaccines (Basel)· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibody responses against heterologous H5N1 strains for an MF59-adjuvanted cell culture-derived H5N1 (aH5n1c) influenza vaccine in adults and older adults.
Sharon S Frey, Eve Versage, Esther Van Twuijver, Matthew Hohenboken

Hum Vaccin Immunother· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity and Safety of MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared with a Nonadjuvanted, Quadrivalent Influenza Vaccine in Adults 50-64 Years of Age.
Airi Poder, Janine Oberije, Jay Meyer, Peter Heymer, Deborah Molrine, Eve Versage

Vaccines (Basel)· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relative Vaccine Effectiveness of Adjuvanted Trivalent Influenza Vaccine over Three Consecutive Influenza Seasons in the United States.
Constantina Boikos, Ian McGovern, Justin R Ortiz, Joan Puig-Barberà, Eve Versage

Vaccines (Basel)· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 3 Randomized, Multicenter, Placebo-Controlled Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of an Adjuvanted Cell Culture-Derived, H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects.
James Peterson, Esther Van Twuijver, Eve Versage, Matthew Hohenboken

Vaccines (Basel)· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analyses of Safety Profile and Homologous Antibody Responses to a Mammalian Cell-Based, MF59-Adjuvanted, A/H5N1, Pandemic Influenza Vaccine across Four Phase II/III Clinical Trials in Healthy Children, Adults, and Older Adults.
Eve Versage, Esther van Twuijver, Wim Jansen, Ad Theeuwes, Daphne Sawlwin

Vaccines (Basel)· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibody responses against heterologous A/H5N1 strains for an MF59-adjuvanted cell culture-derived A/H5N1 (aH5N1c) influenza vaccine in healthy pediatric subjects.
Pornthep Chanthavanich, Eve Versage, Esther Van Twuijver, Matthew Hohenboken

Vaccine· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and pharmacodynamics of multiple doses of BG00010, a neurotrophic factor with anti-hyperalgesic effects, in patients with sciatica.
Pieter Okkerse, Justin L Hay, Eve Versage, Yongqiang Tang, Gerald Galluppi

Br J Clin Pharmacol· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-In-Human, Double-Blind, Placebo-Controlled, Randomized, Dose-Escalation Study of BG00010, a Glial Cell Line-Derived Neurotrophic Factor Family Member, in Subjects with Unilateral Sciatica.
Paul E Rolan, Gilmore O'Neill, Eve Versage, Jitesh Rana, Yongqiang Tang

PLoS One· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis